- Home
- LZ vs OLMA Comparison
LZ vs OLMA Comparison
Compare LZ & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LZ | OLMA |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 949.3M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LZ | OLMA |
|---|---|---|
| Price | $6.19 | $9.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $9.79 | ★ $44.89 |
| AVG Volume (30 Days) | ★ 2.2M | 859.9K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $756,043,000.00 | N/A |
| Revenue This Year | $11.50 | N/A |
| Revenue Next Year | $7.08 | N/A |
| P/E Ratio | $155.75 | ★ N/A |
| Revenue Growth | ★ 10.88 | N/A |
| 52 Week Low | $5.22 | $6.65 |
| 52 Week High | $12.40 | $36.26 |
Technical Indicators
Market Signals| Indicator | LZ | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 38.46 |
| Support Level | $6.17 | $9.06 |
| Resistance Level | $6.75 | $12.37 |
| Average True Range (ATR) | 0.27 | 0.54 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 46.15 | 11.76 |
Price Performance
Historical ComparisonAbout LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.